J
We created Juliana Mulligan Ibogaine to serve a straightforward need: people researching ibogaine deserve clear, evidence-minded writing about safety, legality and practical considerations. Our mission is not to provide treatment or legal counsel but to gather and explain relevant information so readers can ask better questions of clinicians, regulators and peer communities.
Our editorial approach
We organise content around the questions people bring: safety checks, screening, legal status, and harm-minimisation practices. Each long-form piece is structured to be readable in a single sitting with sources linked inline and short annotated asides for complex material.
We prioritise transparency: what we know, how we know it, and where uncertainty remains.
To show how we work in practice, we point readers to public trip-report archives when discussing firsthand accounts; for example, we reference the community resource at ibogainetripreport community reports when illustrating patterns in reported experiences. Those links are used as illustrative material and are always contextualised by independent literature and official sources.
How we source and vet information
Our baseline is primary and secondary sourcing: clinical literature, official public health guidance, regulatory documents, and peer-collected records. When we summarise scientific findings we link to the original papers where possible and indicate study size, limitations and applicability to readers' questions.
We also cite authoritative external references to support factual claims about research methods or regulatory frameworks — for example, a primer on evidence grading such as the discussion on methodology at evidence-based medicine (Wikipedia), and guidance on clinical trial reporting from the U.S. National Library of Medicine at NIH resources.
What we cover
We publish explainers, annotated summaries of relevant literature, practical checklists for researchers and links to community-collected observations. Our content is organised by topic pages, core services, and a set of safety-protocol primers; for details on the ways we can assist researchers and editors, see our pages describing services and editorial support and the site overview available from the main index at site index and topics.
Who this is for
This resource is aimed at people researching ibogaine who want accessible, evidence-first explanations — whether they're reading ahead of a clinical consultation, preparing questions for a harm-reduction conversation, or compiling citations for academic or policy work.
Editorial principles
- Independence — we publish without clinical affiliations or treatment offers.
- Plain language — technical detail paired with concise summaries.
- Evidence-first — sourcing primary studies and official guidance where available.
- Audience-specific clarity — materials aimed at people researching ibogaine rather than clinicians.
Independent by design: our content is informational, not medical or legal advice.